Table 3.
Author | Year | Clinical Study Design | N of Patients | Study Groups | RT Dose | RT Technique | Drugs | Key Results |
---|---|---|---|---|---|---|---|---|
Morganti et al. [40] | 2014 | retrospective | 955 | 3: RT, CT, or CRT | 45-60 Gy | na | fluoropyrimidines | OS: CRT 39.9 mts CT 27.8 mts RT 24.8 mts (p > 0.001) |
Parikh et al. [41] | 2015 | retrospective | 1130 | 3: surgery, CT, CRT | 50 Gy | na | gemcitabine | OS: CT vs. surgery HR 0.71 (0.57–0.89) CRT vs. surgery HR 0.84 (0.69–1.02) |
Rutter et al. [39] | 2015 | retrospective | 6165 | 2: CT or CRT | 50 Gy | na | na | CRT vs. CT OS: 23.3 vs. 20 mts 5-y OS: 19.6% vs. 16.5% (p 0.001) |
Osipov et al. [42] | 2017 | retrospective | 102 | 2: CT or CRT | na | na | na | >2 mm resection margin vs. <2 mm: Local RFS: HR 0.20 (0.05–0.88) OS: HR 0.31 (0.14–0.74) |
Kanji et al. [43] | 2018 | retrospective | 102 | 2: CT or CT-CRT | 50 Gy | na | gemcitabine and taxanes, then fluoropyrimidines | CCRT vs. CT OS: HR 0.08 (p < 0.001) DFS: HR 0.23 (p 0.001) |
Hsieh et al. [44] | 2018 | prospective | 588 | 3: CCRT, CRT, CT | 50 Gy | IMRT | gemcitabine | OS: CCRT vs. CT HR 0.40 (0.31–0.50) CRT vs. CT HR 0.31 (0.24–0.40) CRT vs. CCRT (p 0.014) |
Xu et al. [45] | 2018 | retrospective | 804 | 3: surgery alone, CT, CRT | 50 Gy | IMRT | gemcitabine | CRT vs. no CRT: OS 23.7 vs. 17.0 mts p < 0.001 RFS 12.2 vs. 8.5 mts p < 0.001 |
Ma et al. [46] | 2019 | retrospective | 5667 | 3: CCRT, CRT, CT | >45 Gy | na | 5FU or gemcitabine | OS: CCRT vs. CT 23.3 vs. 20.0 CCRT vs. CRT 23.4 vs. 20.8 (p > 0.001) |
Abbreviations: 5FU = 5-fluorouracil; CT = chemotherapy; CCRT = chemotherapy followed by concurrent chemoradiation therapy (CRT); DFS = disease-free survival; mts = months; OS = overall survival; na =, not available; RFS = relapse-free survival; RT = radiation therapy; IMRT = intensity-modulated radiation therapy.